<

UCB (EBR:UCB) UCB Media Room: Acquisition of own shares

Transparency directive : regulatory news

12/04/2024 20:00
https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r= CyBv9bezcPT-2BuItTLKIHepbxTbo-2FYbVFPSBekB-2Bmk9X7Kl8shoTE6BsSbYYjHYcOVCrOC= rjYrJUHPDVbu1NKaBE-3Dxz73_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2= FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLN= n-2B6FohpNoV33Er2gDQt7VZGVSwkJ714ZGJd-2BJhjw0OltVPiJAX1XLKdhqHDTmPxho3eG191= cg9PY5gugHQ0hY4uze0TYr6jye1l4pmoIzXtnHbbh58Hbmka3YSN65Q08gQRpmwwA-2FkTka0LB= fHxuRn7Gdp5hCr8LLeSEdBdRSP76cQkrP8t7NX0T-2BlhqDvbRgSFZM-2FZ2Uzn7LAD0UI-2Fw9= yVFhkjFySkPslswOyPH8FZD2JKnwzpDYYk-3D ** Acquisition of own shares ------------------------------------------------------------ Brussels (Belgium), 12 April 2024 =E2=80=93 20:00 (CEST) =E2=80=93 Regulate= d information =C2=A0 Acquisition of own shares In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi= ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB= =E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose= s certain information in relation to its Share Repurchase Program 2024.=C2= =A0 Under this program, UCB has requested a financial intermediary to repurchas= e up to 1,300,000 UCB shares on its behalf under the terms of a discretiona= ry mandate agreement with initial validity until 30 June 2024, effective as= from 02 April 2024, to cover current and future obligations under UCB's Lo= ng Term Incentive Plans for its personnel. In the framework of this Share Repurchase Program 2024, UCB repurchased 112= ,680 UCB shares on Euronext Brussels in the period from 05 April 2024 up to= and including 11 April 2024, as follows:=C2=A0 https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r= CyBv9bezcPT-2BuItTLKIHepbtZNcDtG8Y2MhOGwqLBpzbfzCabMxn-2BYlAjPsA7EoHI63-2BG= ps0KzdM1wiqBQq3Px8hsVRdz9QPCskoFaO6dwy6vT9d_2dCLUNbuBjhX746-2FvM63L9Hyn3KnT= FGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIx= s8cV3s33SbkEZvEGLNn-2B6FohpNoV33Er2gDQt7VZGVSwkJ714ZGJd-2BJhjw0OltVPiJAX1XL= KdhqHDTmPxho3eG191cg9PY5gugHQ0hY4uze0TYr6jye4tTE2Jvt7BcFxR101amolnLqT1TSDvj= UAFsy2Ym-2FehCAOSyOMdsDHocrqayUq28zzywecpEizzYa4h7uwaXTtcR7vbOe-2FBaiHeW493= JY4We7jkqaC3Nn8LPqqkYqhzAd1iSeWs8xaNG4Wf4Kq46Eog-3D This press release is available on UCB SA/NV=E2=80=99s website via the foll= owing link (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUz= lo7XKIuSly0rC4Oa12rFuiaXNgb0F6L7ybSCidGRlUFwTxzrkzCt6dOMzdZPcjqPbg8jratFLJj= fTg-3D-3DpmFa_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BI= fez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV= 33Er2gDQt7VZGVSwkJ714ZGJd-2BJhjw0OltVPiJAX1XLKdhqHDTmPxho3eG191cg9PY5gugHQ0= hY4uze0TYr6jyexhtrv9sQtWBUbw-2FSd-2F-2FvN68Vf42uhOAaO6HAAIl3F6OVcfknAbxWkqW= duWi4Y2MjVMnFKBcqn2t2HnKuTLLGUFuw0KpzdsMmoEaFeBM7kDkJncYekojwnQU0fXfNF98f-2= B1QH5Cak1sKI5RkrxqafLU-3D . For further information, contact UCB:=C2=A0 Investor Relations Antje Witte=C2=A0 T +32 2 559 94 14 Antje.Witte@ucb.com Corporate Communications Laurent Schots=C2=A0 T+32 2 559 92 64 laurent.schots@ucb.com =C2=A0=C2=A0 =C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With approximately 9,000 peopl= e in approximately 40 countries, the company generated revenue of =E2=82=AC= 5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Foll= ow us on Twitter: @UCB_news. =C2=A0 GenericFile 240412 - Acquisition actions propres FR Final (https://u7061146.ct.sendgrid= .net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepbtZN= cDtG8Y2MhOGwqLBpzb1gPmvBt-2FSw4Oh-2BLPbNJzKG35lTTsG47hcah3iDOP-2BC0-3D4hZm_= 2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mp= lcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33Er2gDQt7VZGV= SwkJ714ZGJd-2BJhjw0OltVPiJAX1XLKdhqHDTmPxho3eG191cg9PY5gugHQ0hY4uze0TYr6jye= yQ9JboJjHbaxQmTK9kYuUcx16-2Fto85xAR8N-2FvuCXMdmstYf5SdJEvd7FAVLI1iI1KVtz7Va= nYpg-2FBHuOp8KSAttZnCZ2IvivgNwKY5xN7rfaLcHun5YEWF8-2F5Mnx7W-2BEryN4FQISW44A= 1-2BIBTbF6CQ-3D GenericFile 240412 - Verwerving van eigen aandelen NL Final (https://u7061146.ct.sendgr= id.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepbt= ZNcDtG8Y2MhOGwqLBpzb8xpYi-2F4jmbyBzBzlyrFIvbm1vn8ooD-2F24lO9DWycEgY-3Dsdfg_= 2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mp= lcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33Er2gDQt7VZGV= SwkJ714ZGJd-2BJhjw0OltVPiJAX1XLKdhqHDTmPxho3eG191cg9PY5gugHQ0hY4uze0TYr6jye= z3AuCx-2FxyzsgzDDCI4eG8THlZxXMnJfHyVo-2Bw-2FT4uHMQcqAwjlB-2FqNGuB193ivRuD1R= jGwmt880Sqn5Z09ft9-2Bg5AU4xJZJ9gFf92EAcBXI2yVH-2FEVCpHravyMguw0MxGtIyb0ajWH= wHd-2FuO8d65XY-3D GenericFile 240412 - Acquisition of own shares ENG Final (https://u7061146.ct.sendgrid.= net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepbtZNc= DtG8Y2MhOGwqLBpzboeCx5Shqlw-2BD47EWFRfPlDk2E6oMVWDI6iQ1R-2FtHl74-3D9SUx_2dC= LUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcE= W6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33Er2gDQt7VZGVSwk= J714ZGJd-2BJhjw0OltVPiJAX1XLKdhqHDTmPxho3eG191cg9PY5gugHQ0hY4uze0TYr6jye-2F= EPjA7BvMyWFRgTtYGZvlN0uAcpN5TvoqgHODRp3Ry6QHZVcdv96KSEvmhnOUOXtSKBtsjUWmeQA= M4yzjHppQd6TiDyZqYS6YgNjJA4ZWZ9omfqNClK08PEw8WT72b1fc-2FA4g-2BapCbJ0ah-2Fg0= 2zU8A-3D Image Chart 1 April 12 2024 (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001= .gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepbtZNcDtG8Y2MhOGwqLBpzbfzCabM= xn-2BYlAjPsA7EoHI2aGwGr9MrU-2B9vkTT5Xbo3o-3D4ibl_2dCLUNbuBjhX746-2FvM63L9Hy= n3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93= DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33Er2gDQt7VZGVSwkJ714ZGJd-2BJhjw0OltVPiJ= AX1XLKdhqHDTmPxho3eG191cg9PY5gugHQ0hY4uze0TYr6jye1vBQI7nSPbuwgpTQioOk1xkooc= sKebAVavWnSxwC8tNJCsynCGkC1-2FaHmle41mNrNjn9gzTnGy-2B-2Br2plO1Tsax6ka4mXbCr= k5yrky4z3I3Df3cBWSgEa-2FwUyVaapQbjLXmOXrxPtNORd9xy4HUCfjQ-3D ______________________ If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIu= Sly0rC3nfmD42E6tJ6HwHGmqtXbhtXDlQ2cTEdRpWV-2BrYPIUNb2TKBBlPaLRSZOzusq09mJ2y= RbI6vLUIO0t28i6O2yv97ekiHBOh7xYAYGrCfirqaLzIzRytZxwK89cX7N74WdRQ7l7nEWK-2BN= sSHAbkaIMs-3DPfFk_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt= -2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6Foh= pNoV33Er2gDQt7VZGVSwkJ714ZGJd-2BJhjw0OltVPiJAX1XLKdhqHDTmPxho3eG191cg9PY5gu= gHQ0hY4uze0TYr6jyezEjvENOSQ6KKNTfJX2q0-2BYO1H0mxA7-2BzbkpSO2ub4vrk93VScsmqR= KPqF0MvMUdBswfnSS-2B-2BOGMkWAayfh3MddJZBsAyoZ6Z9tdv5RjurypTG-2BXRurIQIJmaw7= 0ttd7W6cLiT-2BqBYGvcE761snTS5k-3D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium

source : webdisclosure.com



Other stories

26/12/2024 21:32
26/12/2024 21:05
27/12/2024 00:44
26/12/2024 13:32
26/12/2024 19:56
27/12/2024 00:30
26/12/2024 23:37
26/12/2024 23:14
26/12/2024 23:59
26/12/2024 23:08
26/12/2024 22:49
27/12/2024 02:06
26/12/2024 18:15
26/12/2024 13:55
26/12/2024 12:38
26/12/2024 12:58
26/12/2024 13:29
26/12/2024 21:33
26/12/2024 02:44
26/12/2024 12:14
26/12/2024 12:57
26/12/2024 14:49
26/12/2024 23:00
26/12/2024 23:14
26/12/2024 23:18
26/12/2024 21:12
27/12/2024 01:15
26/12/2024 20:52
26/12/2024 19:50
27/12/2024 00:41
26/12/2024 13:30
26/12/2024 06:00
26/12/2024 19:54
26/12/2024 10:00
26/12/2024 17:50
26/12/2024 22:05
26/12/2024 08:00
27/12/2024 00:20